Claims for Patent: 8,637,553
✉ Email this page to a colleague
Summary for Patent: 8,637,553
Title: | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Abstract: | A compound of Formula (I): ##STR00001## salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3. |
Inventor(s): | Boyer; Stephen (Hilden, DE), Dumas; Jacques (Bethany, CT), Riedl; Bernd (Wuppertal, DE), Wilhelm; Scott (Orange, CT) |
Assignee: | Bayer Healthcare LLC (Tarrytown, NY) |
Application Number: | 10/895,985 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,637,553 |
Patent Claims: |
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an isolated stereoisomer of a pharmaceutically acceptable salt thereof ##STR00006##
2. A pharmaceutically acceptable salt of a compound of Formula I ##STR00007## which is a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid. 3. A compound which is 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridi- ne-2-carboxylic acid methylamide, or a pharmaceutically acceptable salt thereof. 4. A pharmaceutically acceptable salt of a compound of claim 3 which is a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid. 5. A compound which is a hydrochloride, benzenesulfonate, or methanesulfonate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-2-fluoro-(4-(2-(N-methylcarbamo- yl)-4-pyridyloxy)phenyl) urea. 6. A pharmaceutical composition comprising a compound of claim 1 and a physiologically acceptable carrier. 7. A pharmaceutical composition comprising a compound of claim 2 and a physiologically acceptable carrier. 8. A pharmaceutical composition comprising a compound of claim 3 and a physiologically acceptable carrier. 9. A pharmaceutical composition which comprises a pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-2-fluoro-(4-(2-(N-methylcarbamo- yl)-4-pyridyloxy)phenyl) urea and a physiologically acceptable carrier. 10. A compound which is a metabolite of the compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an isolated stereoisomer of a pharmaceutically acceptable salt thereof, ##STR00008## where the metabolism site is either one of the two urea nitrogen atoms, or the pyridine nitrogen atom, or the methylamide functionality, or any combination of the above. 11. A compound of which is a metabolite of the compound of Formula (I), ##STR00009## where a) either urea nitrogen atom carries a hydroxyl group, or b) the pyridine nitrogen atom is oxidized, or c) the amide functionality is de-methylated, or d) the pyridine nitrogen atom is oxidized and the amide functionality is de-methylated, or e) either urea nitrogen atom carries a hydroxyl group and the pyridine nitrogen atom is oxidized, or f) either urea nitrogen atom carries a hydroxyl group and the amide functionality is de-methylated, or g) either urea nitrogen atom carries a hydroxyl group and the pyridine nitrogen atom is oxidized and the amide functionality is de-methylated. 12. A compound which is: 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridi- ne-2-carboxylic acid amide, 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-1-hydr- oxy-pyridine-2-carboxylic acid methylamide, or 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-1-hydr- oxy-pyridine-2-carboxylic acid amide. 13. A compound of Formula (I) ##STR00010## 14. A pharmaceutical composition comprising the compound of claim 13 and a physiologically acceptable carrier. 15. A salt of a compound of Formula (I) ##STR00011## 16. A pharmaceutical composition comprising a salt of claim 15 and a physiologically acceptable carrier. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.